Record revenue and adjusted EBITDA of $247.4 million and $90.3 million, respectivelyRecord high value transactions in the Saskatchewan Land ...

Collaboration Revenue: There was $2.3 million of collaboration revenue for the year ended December 31, 2024, as compared to no collaboration revenue for the year ended December 31, 2023. The increase ...

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, ...

HUYA Inc. ('Huya' or the 'Company') (NYSE: HUYA), a leading game live streaming platform in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December ...

The Afghan father of two worked for a U.S.-backed organization in Kabul, which put him at risk of Taliban retribution. Now he is among thousands of newly arrived refugees who lost financial assistance ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Cash and cash equivalents, restricted cash, short-term investments and time deposits were RMB41.96 billion (US$5.75 billion) as of December 31, 2024Quarterly total revenues were RMB16.11 billion, a 59 ...

Flotek Industries has doubled its share price in six months, outperforming its peers in the oilfield services sector. Read why I remain bullish on FTK stock.

BrightSpire Capital, Inc. (NYSE: BRSP) ("BrightSpire Capital" or the "Company") today announced that the Company’s Board of Directors has declared a dividend of $0.16 per share of Class A common stock ...

Discover why China's bull market, fueled by generative AI advancements like DeepSeek, is just beginning. Click here to read ...

ZKH Group Limited ("ZKH" or the "Company") (NYSE: ZKH), a leading maintenance, repair and operations ("MRO") procurement ...

BioArctic AB (publ) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy ...